We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Revvity Logo

Revvity

Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments.

Latest Content

Antibodies.
Product News

Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Revvity, Inc. (NYSE: RVTY), announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus.
Decoding Rare Diseases: How Genomics Is Transforming Diagnosis Infographic
Infographic

Decoding Rare Diseases: How Genomics Is Transforming Diagnosis

This infographic explores how genomic technologies are enabling earlier and more precise diagnoses for patients.
Cells.
Product News

Revvity Ignites Scientific Breakthroughs at SLAS2025

Revvity, Inc. is set to unveil its new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29.
Close up of a new born baby's feet.
Product News

Revvity and Element Biosciences Collaborate To Advance Sequencing-Based IVD Neonatal Testing

Revvity, Inc. announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc.
A doctor holding a patients hands.
Product News

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

Revvity, Inc. (NYSE: RVTY), announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone.
Close-up 3D visualization of microbiome cells, showcasing diverse bacteria and microorganisms in a blue-toned environment
App Note / Case Study

Optimizing Recovery of Microbial DNA for 16S Sequencing

This application note explores techniques for effective sample preparation, including selecting the optimal bead media and how to achieve full sample lysis and DNA recovery in both liquid and solid samples.
Abstract illustration of the human gut microbiome, showcasing diverse microbes in a stylized digestive tract on a blue background.
App Note / Case Study

Boost the Efficiency of Metagenomic Microbiome Analysis

This application note explores an automated workflow that enhances DNA extraction and sequencing efficiency for stool samples, minimizing human error and delivering high-quality data on microbial communities.
3D molecular visualization of a DNA double helix represented by spheres, with particles floating in a dark green background
Whitepaper

Improving Long-Read Next Generation Sequencing: What You Should Know

This whitepaper explores the applications of long-read sequencing technologies and best practice strategies to overcome challenges in sample preparation.
A robotic hand and human finger touch, emitting light, surrounded by digital circuits and neural patterns in a futuristic scene.
App Note / Case Study

Leverage AI To Perform Cell Segmentation on Brightfield Images

This application note showcases how an AI-based module has been trained to analyze brightfield images for cell segmentation, allowing insights into cell proliferation and cell morphology without the need for manual drawing on images.
Double helix structure of DNA.
Product News

Revvity Broadens Relationship With Genomics England To Advance Genomics in the UK

Revvity, Inc. (NYSE: RVTY), announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom.
Advertisement